Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the challenges and lack of progress in improving burn care outcomes for patients aged 65 and older, highlighting the urgent need for tailored treatment protocols and better understanding of their long-term care needs.

This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.

This study found that quality of life was significantly impaired among Chinese rosacea patients, especially those aged 21-40, with recent disease onset, appearance-dependent jobs, and severe symptoms.

This study found that platelet-rich plasma treatment significantly improved erectile function and restored neural structures in aged rats with erectile dysfunction, suggesting potential benefits for geriatric patients.

This study found that topical application of mitochondrial electron transport chain inhibitors stimulated hair follicle stem cell activation and hair regrowth in aged mice by promoting lactate production.

In this review, researchers explored how PGC-1α might improve aged skin barrier function by influencing mitochondrial function and reducing inflammation, factors that are linked to epidermal health during aging.

This study highlights that topical ruxolitinib cream is FDA-approved for mild to moderate atopic dermatitis and nonsegmental vitiligo in patients aged 12 and older, but its use in other skin conditions like frontal fibrosing alopecia remains under-researched and needs further exploration in clinical practice.

This study suggests that a hair lotion containing methyl myristate loaded in cationic niosomes may effectively accelerate pigmentation in aged C57BL/6 mice compared to free methyl myristate.

In this study using the TriNetX Research Network, men with low serum testosterone levels were found to have an increased risk of developing an initial kidney stone, particularly in those aged 33-44, compared to men with normal testosterone levels.

In this study, seborrheic dermatitis was most prevalent among middle-aged adults and men, with patient presentations peaking during the winter months.

In this study, it was found that 39.6% of the women in Isfahan aged 20 to 70 had androgenetic alopecia, and lower ferritin levels were linked to more severe cases.

This analysis of clinical records found that the highest incidence of alopecia patients visiting a Korean medicine clinic were aged 20-30, with androgenic alopecia being the most common type.

This study found that 1 mg/day of finasteride significantly reduced serum PSA concentrations in men with androgenic alopecia aged 40–60 over 48 weeks, suggesting implications for prostate-cancer screening in this population.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

In this survey study, 259 hospitalized COVID-19 patients aged 18-59 reported long-term symptoms, with 92.5% experiencing ongoing issues such as hair loss, fatigue, and shortness of breath, highlighting the prevalence of long COVID-19 conditions.

This study identified recurrent dry cough, wheezing, and respiratory discomfort as key symptoms valued in early asthma diagnosis among children aged 5 to 12.

This study found that alopecia areata can affect individuals across various ages but is predominantly observed in males aged 21-40, and may be linked to autoimmune diseases, thyroid issues, and inflammation.

Higher unemployment rates are linked to increased suicide rates, especially in men aged 25-49 in France.

This animal study found that transparent porcine-derived Type I atelocollagen increases skin thickness and regenerates elastic fibers in aged mice, suggesting its potential as a skin booster for rejuvenation.

This study found that supplementation with micronized and emulsified ferric pyrophosphate effectively improved lab test results and reduced iron deficiency symptoms in patients aged 19-70, with the majority reporting good tolerance and few side effects.

This study found that periodic red light exposure increased histone acetylation and activated metabolic processes in aged mice, leading to enhanced fatty acid oxidation and the mitigation of cellular aging by influencing gene expression and metabolic regulation.

In this study, periodic exposure to red light in aged mice led to increased histone acetylation and activated mitochondrial fatty acid oxidation, which collectively mitigated cellular aging by modulating metabolism, inflammation, and gene expression.

This case report from Dr Batra’s Homeopathy Clinic observed that an individualized classical homeopathic treatment successfully improved hair parameters and quality of life in a middle-aged male with Grade V androgenetic alopecia, sustaining remission for over six months despite previous conventional therapies proving unsatisfactory.

This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.

In this study using mouse models, researchers found that elevated IL-17a in aged olfactory epithelium impairs olfactory function, while IL-17a inhibition promotes regeneration and mitigates age-related decline.

This study observed that omalizumab may induce alopecia, particularly in females aged 18-60, though establishing a direct cause-effect link remains challenging. Alopecia areata was noted as a possible uncommon, yet transient, hair loss type associated with omalizumab.

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This study reported that most androgenetic alopecia patients in Trujillo were male, aged 31–39, with a family history of the condition, showing specific hair loss patterns and a disease duration of 1–5 years.

This population-based study found that n-3 fatty acid intake may not benefit and could potentially harm hair loss improvement in middle-aged or elderly men, as higher n-3 intake was associated with a greater risk of non-improvement in male pattern hair loss.

In this study, researchers found that bicalutamide was more effective and had a better safety profile than spironolactone for treating female-pattern hair loss in women aged 18 to 50, based on the Sinclair scale and photographic assessments after 24 weeks of treatment.